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Epigenetics refer to inheritable changes beyond DNA sequence that control cell identity and morphology. Epigenetics play key
roles in development and cell fate commitments and highly impact the etiology of many human diseases. A well-known link
between epigenetics and human disease is the X-linked MECP2 gene, mutations in which lead to the neurological disorder, Rett
Syndrome. Despite the fact that MeCP2 was discovered about 20 years ago, our current knowledge about its molecular function is
not comprehensive. While MeCP2 was originally found to bind methylated DNA and interact with repressor complexes to inhibit
and silence its genomic targets, recent studies have challenged this idea. Indeed, depending on its interacting protein partners
and target genes, MeCP2 can act either as an activator or as a repressor. Furthermore, it is becoming evident that although Rett
Syndrome is a progressive and postnatal neurological disorder, the consequences of MeCP2 deﬁciencies initiate much earlier and
before birth. To comprehend the novel and challenging concepts in MeCP2 research and to design eﬀective therapeutic strategies
for Rett Syndrome, a targeted collaborative eﬀort from scientists in multiple research areas to clinicians is required.
1.Introduction
The term epigenetics refers to inheritable changes in gene
expression that control cellular phenotype and fate decisions
without alterations in the underlying DNA sequence [1].
In eukaryotes, two main epigenetic regulations are exerted
through modiﬁcations on DNA and DNA-bound histone
proteins. In general, histone modiﬁcations are dynamic
and include acetylation, methylation, isomerization, phos-
phorylation, sumoylation, and ubiquitination [1, 2]. The
combination of such modiﬁcations confers enormous ﬂex-
ibility in terms of functional response of an individual cell
towardsextracellularsignalsandenvironmentalstimuli.Cer-
tain modiﬁcations such as histone methylation can display
additional layers of complexity regarding their methylation
degree and undergo mono-, di-, or tri-methylation of ly-
sineresidues[2,3].Furthermore,combinationsorsequential
additions of diﬀerent histone marks can aﬀect the chro-
matin organization and subsequently alter the expression
of the corresponding target genes [4]. Conventionally, DNA
methylation was considered to be a stable epigenetic mark,
although this notion is being challenged by recent reports
of active DNA demethylation [5]. In mammals, DNA meth-
ylation strictly happens at the cytosine residues in the
context of CpG dinucleotides. The methylation of DNA
molecules is processed by a group of enzymes called DNA
methyltransferases (DNMTs). The mammalian DNMT fam-
i l yc o n s i s t so f5p r o t e i n s( D N M T 1 ,2 ,3 A ,3 B ,3 L ) .D N M T 1
is involved in maintaining the DNA methylation pattern
during replication, while DNMT3A and DNMT3B act as
de novo methyltransferases. DNMT3L is essential for the
establishment of maternal genomic imprints during oocyte
development, and DNMT2 is classiﬁed as part of the DNMT
family; however it has very weak catalytic activity [6].2 Neural Plasticity
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Figure 1: The diverse functions of MeCP2 in gene regulation and chromatin organization.
DNAmethylation isoftenassociated with transcriptional
repression and has been linked to the tissue-speciﬁc regu-
lation of genes [7], expression of imprinted genes [8], and
X-chromosome inactivation in females [9]. In general, DNA
methylation aﬀects gene expression in two ways: (i) directly,
by altering the binding sites of transcription factors, or (ii)
indirectly, via recruitment of proteins that recognize and
bind to the methylated DNA and in turn modulate gene
expression. The ﬁrst group of proteins that were discovered
with the potential of binding to methylated DNA were the
MBD (methyl-binding domain) protein family members.
The mammalian MBD family consists of 5 nuclear proteins,
MBD 1–4 and MeCP2 (Methyl CpG binding protein 2).
With the exception of MBD3, all MBD proteins share a
conservedmethyl-binding domain, through which they bind
to methylated DNA [10]. MBD3 lacks such ability due to
ac r i t i c a lm u t a t i o ni ni t sM B Dd o m a i n[ 11]. MECP2i s
an X-linked gene, which was discovered as the prototype
member of the DNA methyl binding proteins (MBPs) [12].
MutationsinMECP2aretheprimary causeofRettSyndrome
(RTT), a neurological disorder predominantly aﬀecting
youngfemales.RTTischaracterized byanapparentlynormal
development for the ﬁrst 6–18 months after birth, followed
by regression of acquired motor and language skills [13–
15]. In addition to Rett Syndrome, mutations in MECP2
havebeenobservedinpatientswithclassicalautism,neonatal
encephalopathy, and X-linked mental retardation [16–19].
StudiesonMeCP2haveyieldedsurprising resultsinterms
of the diversity of its functions (Figure 1)w i t he n o r m o u s
potential for epigenetic regulation of target gene expression.
MeCP2 was initially identiﬁed as a methyl-binding protein
[20]. Further investigations on MeCP2 function led to
the discovery of its role as a transcriptional repressor and
association with corepressor complexes such as mSin3A and
HDACs [21, 22]. This was not surprising, since DNA methy-
lation itself was considered to be a repressive mark. However,
a genomewide search for MeCP2 genomic distribution in
SH-SY5Y cells led to two surprising observations: (i) MeCP2
was found to beassociated often with transcriptionally active
genes; (ii) only 2.2% of the most methylated promoters were
bound by MeCP2. The presence of MeCP2 at the active
promoters was later observed in mouse hypothalamus,
where MeCP2 was observed to be bound to approximately
85% of genes which were misregulated by overexpression
or absence of MeCP2 [23]. These studies highlight the
many facets of MeCP2 functions and emphasize the need
to further study its known functions. In this review, we
will discuss the role of MeCP2 in chromatin structure and
nuclear architecture of neurons, its competition with the
linker histone H1, the MECP2 transcript products and
diverse functional domains of MeCP2 protein, as well as
MeCP2 expression and genomic targets in neurons and glia.
2.TheMECP2 Gene Structureand
ItsSpliceVariants
The MECP2 gene maps between L1CAM and the RCP/GCP
loci in Xq28 and undergoes X-Chromosome InactivationNeural Plasticity 3
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Figure 2: MECP2 gene and protein isoforms. Schematic illustration of the gene structure of MECP2 and the diﬀerent domains of the two
protein isoforms,MeCP2E1 andMeCP2E2. TheprimaryaminoacidcompositionoftheN-terminus ofMeCP2E1 andMeCP2E2 isdepicted.
(XCI) in females [24, 25]. The genomic locus of MECP2
spans approximately 76kb and consists of four exons encod-
ing two diﬀerentisoforms(MeCP2E1and MeCP2E2),dueto
alternate splicing of exon 2 (Figure 2). The more abundant
E1 isoform contains 24 amino acids encoded by exon 1 and
lacks the 9 amino acids encoded by exon 2, whereas the start
site for the E2 lies within the exon 2 [26]. Of the two iso-
forms, MECP2E1is more eﬃciently translated and show 10X
more expression than MECP2E2 in brain. Mecp2 has a large,
highly conserved 3UTR that contains multiple polyadenyla-
tion sites. Alternative 3UTR usage leads to three distinct
transcripts, short 1.8kb and long 10kb transcripts, with the
latter including a highly conserved (8.5kb) 3UTR, and a
third additional low abundance transcript of approximately
5–7kb [27]. MeCP2 is a nuclear protein that is mainly colo-
calized with densely methylated heterochromatin in mouse
cells. The diﬀerential expression of Mecp2/MECP2 tran-
scripts can be subjected to tissue- and developmental stage-
speciﬁc regulation. In the brain, diﬀerential transcript ex-
pression patterns for the two isoforms have been detected
[28]. The transcript levels are high during embryogenesis
withapostnataldecrease,butincreasingagaintowardsadult-
hood. On the other hand, the protein levels are low during
embryogenesis and increase postnatally upon neuronal mat-
uration [29].
MeCP2E1andE2isoformsonlydiﬀerintheirN-terminal
sequences, sharing the functional MBD and Transcriptional
Repression Domain (TRD), and it seems likely that their
functional properties overlap considerably. However, several
observations point towards the possibility that the two iso-
forms might indeed have subtle yet etiologically relevant
nonredundant functions. The MeCP2E1 isoform has a puta-
tive serine residue within its N-terminus, which is absent
in MeCP2E2 isoform [26]. Furthermore, diﬀerential expres-
sion of the two isoforms at the transcript level has been
demonstrated in the developing mouse brain. Mecp2E2
mRNA was enriched in the dorsal thalamus and layer V of
the cerebral cortex, while more Mecp2E1 transcripts were
detected in the hypothalamus than in the thalamus between
P1 and P21 [28]. Whether this reﬂects a similar variation
of the protein expression pattern remains to be determined.
Mutation analysis in RTT patients has shown that exon
1 mutations can lead to severe RTT phenotypes. Some of
these mutations do not seem to aﬀect the transcription of
MeCP2E2,suggesting thatMeCP2E2alone mightnot beable
to compensate for the loss of MeCP2E1. Althoughmutations
in all domains of MeCP2 have been identiﬁed in RTT
patients, none have been reported to be in the MeCP2E2-
speciﬁc exon 2. However, a number of point mutations have
been identiﬁed that are unique to the MeCP2E1, indicating
thatMeCP2E1-speciﬁcmutationsaresuﬃcienttocauseRTT.
The possibility of functional redundancy between the two
isoforms has been further investigated recently by a group
s t u d y i n gt h eR T Tp h e n o t y p er e s c u ec a p a b i l i t i e so fe a c h
isoform. This study showed that MeCP2E1 alone is capable
of compensating for overall MeCP2 deﬁciency in mice, in
a dose-dependent manner. While MeCP2E2 also achieved
phenotypic rescue, the degree of rescue was signiﬁcantly
higher with MeCP2E1, even at lower dosage levels [30]. The
results of this study suggest that the two isoforms have both
redundant and nonredundant functions.
3. MeCP2ProteinStructure,InteractingProtein
Partnersand PosttranslationalModiﬁcations
The main functional domains of MeCP2 are the MBD, the
TRD, and the C-Terminal Domain (CTD). The MBD facili-
tates binding to methylated CpG dinucleotides and the pref-
erence for adjacent A/T-rich motifs [31]. It is also capable4 Neural Plasticity
of binding to nonmethylated DNA sequences such as the
four-way DNA junctions [32]. However, the role of MeCP2
as a transcriptional repressor is mostly mediated through its
TRDdomain.TheTRDinteractswith corepressorcomplexes
such as mSin3A, further recruiting HDAC1 and HDAC2,
and thereby acting as a link between DNA methylation
and chromatin remodelling [21]. The TRD domain further
facilitates MeCP2 interaction with other partners includ-
ing c-SKI [33], YY1 [34], and YB1 [35]. MeCP2 CTD
is believed to have critical functions, as transgenic mice
lacking MeCP2 CTD display many RTT phenotypes [36].
Recently, MeCP2 has been shown to have dual functions,
also acting as a transcriptional activator via interaction
with CREB [23], although no interacting domain has been
mapped. In vitro, MeCP2 is known to inﬂuence chromatin
compaction and nucleosome clustering [37]. In neurons,
MeCP2 is also known to suppress spurious transcription of
repetitive elements, thereby reducing “transcriptional noise”
[38, 39].
A crucial aspect of MeCP2 that has not been fully ex-
plored is the functional eﬀect of its Posttranslational Mod-
iﬁcations (PTMs). Althoughseveral modiﬁcations have been
detected for MeCP2, only two phosphorylation modiﬁca-
tions have been studied in detail. Of these, phosphorylation
of serine 421 (S421) is linked to neuronal activity and is
known to modulate MeCP2-regulated Bdnf transcription
[40]. Interestingly, phosphorylation of serine 80 (S80) is
removed upon neuronal activity [41]. The same group
detectedtwo otherphosphorylations, S399and S424,in rest-
ing and active neurons, respectively. It would be interesting,
however, to characterize any potential cross-talk between
these speciﬁc PTMs in MeCP2, as seen in histones [42, 43].
Furthermore, knock-in mice models of S80 and S421/S424
showed opposing eﬀects of the modiﬁcations on locomotor
activity, implying diﬀerential function of MeCP2 based on
its PTM [41]. This shows that MeCP2 PTMs enhances
its capability to function dynamically within neurons, thus
emphasizing the necessity of characterizing other PTMs of
MeCP2.
4.The ExpressionPatternof MeCP2
MeCP2 is widely expressed among various tissues, with
higher expression in the brain. Expression studies in rodents,
macaque, and humans have revealed a similar pattern of
heterogeneous MeCP2 expression in brain [29, 44–49].
MeCP2 expression pattern within diﬀerent brain regions
follows the developmentalmaturation of the central nervous
system, being initially detected in the earliest developing
structures such as brainstem and thalamus [29, 49, 50]. In
rodents, MeCP2 expression in the olfactory bulb precedes
synaptogenesis [47, 48]. In general, MeCP2 expression is
highest in neurons, with lower levels of the protein being
detected in glia [51]. Within neurons, MeCP2 expression is
lower in immature neurons and highest in postmitotic neu-
rons [52].TheelevatedlevelsofMeCP2expression inmature
neurons are maintained throughout adulthood, implying its
importance inpostmitotic neuronalfunction. To understand
how MeCP2 deﬁciency impairs brain function, much eﬀort
has been focused on the neuronal cell-autonomous eﬀects
of MeCP2 deﬁciency, due to its high expression in mature
neurons. Previous data indicate that MeCP2 deﬁciency in
n e u r o n si ss u ﬃcient to cause RTT-like neurological pheno-
types in mouse [53]. Recent studies investigating the eﬀects
of Mecp2 deletion in speciﬁc neuronal population have
observed diﬀerential phenotypic outcomes [54, 55]. These
observations imply that various RTT phenotypes might be
generated as a consequence of MeCP2 deﬁciency in speciﬁc
neuronal populations. To date, a possible contribution of
astrocyte dysfunction to RTT has not been fully examined,
mainly due to the previous assumption that MeCP2 is not
expressed in astrocytes.
In 2009, MeCP2 expression in glial cells was shown by
independent groups [51, 56, 57], with signiﬁcantly lower
detection of MeCP2 in glia compared to neurons. MeCP2
deﬁcient astrocytes showed functional abnormalities and
were unable to support proper neuronal growth. Further-
more, MeCP2 deﬁcient neurons were capable of exerting a
nonautonomous eﬀect on MeCP2 wild type astrocytes, and
negativelyregulatingthem.AnotherstudyonMeCP2expres-
sion in microglia showed that MeCP2deﬁciencyin microglia
leads to elevated secretion of glutamate and contributes to
neuronal abnormalities in RTT. Perhaps the strongest evi-
dencetosupporttheeﬀectofMeCP2expressioninastrocytes
in RTT etiology comes from a recent study in which MeCP2
was reexpressed speciﬁcally in astrocytes of an RTT mice
model. Reexpression of MeCP2 in astrocytes alone signif-
icantly improved several phenotypes including improved
locomotion and prolonged lifespan. Restoration of MeCP2
on mutant astrocytes also led to a noncell autonomous eﬀect
on neighboring neurons, rescuing dendrite abnormalities
and increasing the level of V-glut1 [58]. These studies show
the critical role of glial cells in RTT pathology and warrant
further investigation on MeCP2 function in glia.
5. MeCP2 Binds to Methylated DNA
and CompeteswithHistone H1 for
the InternucleosomalDNA
Eukaryotic DNA is compacted into chromatin, which is
made up of nucleosome repeats [59, 60]. The nucleosome
consists of a core particle composed of a histone octamer
associated with DNA and a linker DNA that connects the
core particles bound by one H1 linker histone. The histone
octamer consists of two copies of each of the four histones
H2A, H2B, H3, and H4. Histone H1 or linker histone seals
t w or o u n d so fD N Aa ti t se n t r y / e x i ts i t eo nt h es u r f a c e
of the nucleosome core and thereby stabilizes higher-order
chromatinstructure[61].HistoneH1hasmanyvariantswith
speciﬁcity observed among species, tissue types, and even
developmental stage.
Recent studies have suggested a possible relationship
betweenhistoneH1andDNAmethylation[62,63].Microar-
ray analysis of embryonic stem cells in which three H1
variants (H1c, H1d, and H1e) have been silenced revealed
that approximately one third of the genes showing alteredNeural Plasticity 5
expression pattern were regulated by DNA methylation. A
quantitative reduction in the extent of DNA methylation
at speciﬁc CpG dinucleotides within the imprinting control
regions of the H19-Igf2 and Gtl2-Dlk1 genelociwasobserved
in these cells. It is interesting to note that most of these
genesareknowntoberegulatedbyMeCP2(Table 1).In vitro,
MeCP2 can compete with histone H1 and bind linker DNA
[64, 65]. In vivo,linkerH1and MeCP2show similar mobility
in the nucleus and share the same internucleosomal binding
sites, evidentby FluorescenceRecovery AfterPhotobleaching
(FRAP) studies [66, 67]. Furthermore, neuronal nuclei
lacking MeCP2 show 2-fold upregulation of histone H1
expression [39]. These observations suggest that in neurons,
MeCP2 and histone H1 may share similar functions, at least
in part with respect to chromatin organization.
6.MeCP2 GenomicDistributionsand
Target Genes
By interpreting DNA methylation, MeCP2 modulates tran-
scriptional repression and silencing of speciﬁc target genes.
In neurons, MeCP2 closely tracksthe intensity of methylated
DNA [39]. Recent studies on MeCP2 genomic distribution,
however, indicate that it occupies both methylated and
unmethylated DNA [82]. Although DNA methylation is
consideredtobea stablemodiﬁcation, itisbecomingevident
that in the brain, reduction of DNMTs or reduced MeCP2
association may result in decreased DNA methylation, a
process previously thought to be irreversible. To fully
understandthefunctionalroleofMeCP2inthepathobiology
of RTT, and to develop eﬀective therapeutic strategies, a
comprehensive knowledge of MeCP2 genomic targets is
essential. To this end, several research groups have attempted
to identify global gene expression alterations caused by
MeCP2 dysfunction in neuronal and nonneuronal tissues
from RTT patients and mice models. However, in most
cases these studies have generated only a small and mostly
nonoverlapping list of target genes [23, 68–80]( Table 1).
Also, direct association of these identiﬁed targets towards the
pathophysiology of RTT has not been established in most of
these studies. One exception to this would be Brain-Derived
Neurotrophic Factor (BDNF). In 2003, two independent
groups demonstrated MeCP2 binding to methylated CpG
sites near the promoter III of Bdnf in resting neurons
[70, 71]. Membrane depolarization of these neurons by
KCl treatment led to the dissociation of MeCP2 from the
Bdnf promoter. Two mechanisms have been proposed for
the dissociation of MeCP2: (i) reduced CpG methylation
at the MeCP2 binding site following neuronal activation
[70] and (ii) phosphorylation of MeCP2 at speciﬁc lysine
residues [71]. Recent studies in mice models have further
providedinvivoevidenceforfunctionalinteractionsbetween
MeCP2 and Bdnf. Experiments on an RTT mice model
have shown that knockout of Bdnf exacerbated the RTT
phenotypes,whereasoverexpressionofBdnf rescued asubset
of RTT-like phenotypes [83]. ChIP-based experiments in
neonatal mouse brain identiﬁed two MeCP2 binding sites in
an imprinted gene cluster in chromosome 6 [81]. Two genes
within this cluster, Dlx5 and Dlx6, showed approximately
twofold increases in expression, in MeCP2-null mice brain.
The study also showed alterations in histone modiﬁcations
and the formation of a higher-order chromatin loop at
the silenced chromatin of the Dlx5-Dlx6 locus in wild
type and the lack of formation of the chromatin loop in
RTT patients. This provided evidence for a novel mode of
gene repression by MeCP2, although a similar mechanism
of repression has not been shown for any other MeCP2
targets.
7.Human DiseasesAssociatedwith
MECP2 Mutations
MeCP2 mutations are mostly sporadic, occurring preferen-
tially as C > T transitions of CpG dinucleotides and mostly
on the paternal X chromosome [84, 85]. As mentioned
earlier, MECP2 mutations are mainly associated with Rett
Syndrome,a progressive postnatal neurologicaldisorderpre-
dominantlyaﬀectingfemaleswith anincidenceof1in10,000
[86].RTTis characterized by an apparentlynonsymptomatic
phase for the ﬁrst 6–18 months of age followed by apraxia,
deceleration of head growth, gait abnormalities, stereotypic
hand movements, and mental retardation. The lifespan of
RTT patients is variable, and some patients survive up to 70
years of age [87, 88]. In male individuals, MECP2 mutation
leads to fatal neonatal encephalopathy [89], Rett syndrome-
like features, and familial X-linked mental retardation with
or without motor abnormalities [89–91]. Male patients with
RTT usually have a short lifespan and very often develop
congenital encephalopathy [92, 93]. MECP2 mutations have
been detected in more than 90% of classical RTT patients.
Approximately 65% of MECP2 mutations causing RTT can
be attributed to 8 recurrent missense or nonsense mutations
within the MBD (R106W, R133C, T158M, and R168X) or
TRD (R255X, R270X, R294X, and R306C) [94, 95].
Previous studies have implicated possible correlations
between these mutations and RTT phenotypes [14, 96].
MeCP2 mutations have also been detected, albeit in very
few patients, with Prader-Willi syndrome [97], Angelman
syndrome [98], nonsyndromic mental retardation [99], and
autistic patients [100]. Currently, Rett Syndrome has no
eﬀective treatment. However, in RTT mice lacking Mecp2,
reactivation of the Mecp2 gene after the onset of disease
can rescue the disease phenotype [101, 102]. This demon-
strates the possibility of RTT gene therapy strategies, where
delivering MECP2 into the aﬀected neurons may indeed
improve RTT symptoms. Creating the ﬁrst generation of
MECP2 isoform-speciﬁc retroviral and lentiviral gene ther-
apy vectors, we showed their eﬃcient and long-term expres-
sion in the adult brain-derived neural stem cells, in their
neuronal progenies, and in the brain microenvironment
[56]. However, the in vivo rescue eﬀect of the gene therapy
deliveryofthesevirusesremainstobeelucidated.Ourstudies
also showed the feasibility of using the endogenous Mecp2
promoter for transgenic MECP2 expression. This is signif-
icant, since one of the critical concerns towards the design
of RTT gene therapy strategy is the prevention of MECP26 Neural Plasticity
Table 1: Known targets of MeCP2.
Gene target Function Cell/tissue type studied Direct association with MeCP2
(cell line used for ChIP) Reference
PCDHB1 Cell adhesion Oral cancer cell lines
(ZA, KOSC2, HSC5,
NA)
Yes (SH-SY5Y)
PCDH7 Cell adhesion Yes (SH-SY5Y) [68]
APBP3 Intracellular signaltransduction Yes (SH-SY5Y)
CLU Extracellular molecular chaperone No (SH-SY5Y)
CRMP1 Component of semaphoringsignal transduction
pathway Yes (SH-SY5Y)
DNMI Vesicular traﬃcking, production of microtubule
bundles, hydrolyzes GTP Yes (SH-SY5Y) [69]
GNBI Integrates signals between receptor and eﬀector
proteins
RTT patient brain
(frontal cortex)
Yes (SH-SY5Y)
APLP1 Enhancer of neuronal apoptosis No (SH-SY5Y)
CO1 Mitochondrial respiratory chain No (SH-SY5Y)
GDI1 Regulates GDP/GTP exchange No (SH-SY5Y)
Bdnf Neuronal plasticity and survival
Mouse E14 cortical
culture Rat E18 cortical
neurons
Yes (mouse E14 cortical culture
Rat E18 cortical Neurons) [70, 71]
Fxyd1 Ion transport regulator for Na, K-ATPase
RTT mice cerebellum
RTT patient’s
brain—superior frontal
gyrus
Yes (adult mice brain, Mecp2 wt
and Mecp2 null mouse;
HEK293T cells)
[72, 73]
Reln
Gtl2
Neuronal layer formation,cell-cell interactions
Growth suppressor RTT mice cerebellum Yes (adult mice brain)
[72]
ID1
ID2
ID3
ID4
Regulation of neuronal diﬀerentiation SH-SY5Y Yes (SH-SY5Y) [74]
IGFBP3 Modulation of IGF functions RTT mice model Yes (HeLa cells; mice cortices) [75]
UBE3A
GABRB3
Ubiquitin ligase
GABA-A receptor
Brain cerebral samples
of RTT, AS, and autism
patients
No (adult mouse cerebellum
samples) [76]
Sst
Oprk1
Gamt
Gprin1
Mef2c
A2bp1
Regulation of cell migration
Signal transduction
Organ morphogenesis
Neurite development
Neuron development and diﬀerentiation
RNA splicing and mRNA processing
RTT mice models
(Mecp2 null and Mecp2
Tg) and control mice;
Hypothalamus
Yes (RTT mice models (Mecp2
null and Mecp2 Tg) and control
mice; Hypothalamus)
[23]
xHairy2a Neuronal diﬀerentiation Xenopus embryos Yes (xenopus neurula stage
embryos) [77]
Sgk1
Fkbp5
Cellular stress response
Hormone signalling
RTT mice model; brain
samples Yes (mice brain tissue) [78]
Uqcrc1 Mitochondrial respiratory chain RTT mice model; brain
samples Yes (adult mice; whole brain) [79]
Crh Stress response RTT mice model; brain
samples Yes (RTT mice brain samples) [80]
Dlx5 Transcription factor Not done Yes (mouse brain) [81]
overexpression.Inhumans,overexpressionofMECP2caused
by duplication of the MECP2 locus leads to a variety of
neurological symptoms including seizures and mental retar-
dation [103–105]. Alternatively, drug treatments can be de-
signed to target proteins, which may compensate for MeCP2
loss in neurons. One study, in particular, has provided great
hope towards pharmacological treatment of RTT in the fu-
ture. Treatment of an RTT mice model with the active pep-
tide fragment of IGF-1 signiﬁcantly improved many disease
phenotypes and extended the overall lifespan of the miceNeural Plasticity 7
[106]. The generation of RTT-speciﬁc iPS (induced Pluripo-
tent Stem) cells has provided an ideal platform to analyze
potential pharmacological treatments for Rett Syndrome
[107, 108].
8.ClosingRemarks
One of the most studied genes to link epigenetics to human
disease is the X-linked MECP2 gene. MECP2 mutations
lead to Rett Syndrome and are also associated with a broad
spectrum of neurological disorders. Despite the impressive
progress on our understanding about MeCP2, there are still
many fundamental questions remaining to be addressed;
at the methylated DNA, does MeCP2 dimerization require
hetero- or homodimerization? Do MeCP2 isoforms show
diﬀerential expression and/or function in CNS and are they
developmentallyregulated?Whatare thefactors thatregulate
MeCP2 expression and splicing within various tissues? And
ﬁnally, does MeCP2 act as a nonspeciﬁc DNA methyl
binding protein on methylated DNA or does it recognize
and prefer particular sites within the genome and what is
the contribution of its interacting protein partners towards
deﬁning the speciﬁcity and sensitivity of such genomic
distribution? A comprehensive knowledge of these unan-
swered questions will help to understand how the products
of a single gene, such as MECP2, have such vast functional
properties.
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